Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Partial nephrectomy for localized RCC

Cahn D et al. AUA Annual Meeting, Abstract PD07-04

Key clinical point: Many patients who could undergo partial nephrectomy are still receiving radical nephrectomies.

Major finding: In 2014, 53% of patients with pT1a or pT1b RCC underwent partial nephrectomy.

Study details: Retrospective analysis of 142,000 patients.

Disclosures: The study was funded internally. Dr. Cahn reports having no relevant financial disclosures.

Read the article.

Citation:

Cahn D et al. AUA Annual Meeting, Abstract PD07-04

This Week's Must Reads

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018

Must Reads in Renal Cell Carcinoma

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018